Table 3.
Probability ranks for primary and secondary endpoints.
| Treatment | Pbest | SUCRA |
|---|---|---|
| CV death or HF hospitalization | ||
| Placebo | 0.29 | 3.91 |
| SGLT2i | 77.24 | 99.97 |
| Vericiguat | 15.92 | 61.54 |
| Omecamtiv mecarbil | 6.55 | 34.58 |
| CV death | ||
| Placebo | 1.49 | 24.76 |
| SGLT2i | 61.14 | 95.09 |
| Vericiguat | 25.89 | 60.85 |
| Omecamtiv mecarbil | 11.48 | 19.30 |
| Any death | ||
| Placebo | 3.66 | 23.49 |
| SGLT2i | 64.97 | 96.92 |
| Vericiguat | 28.40 | 53.75 |
| Omecamtiv mecarbil | 2.97 | 25.83 |
| HF hospitalization | ||
| Placebo | 0.48 | 6.40 |
| SGLT2i | 78.21 | 99.99 |
| Vericiguat | 19.12 | 59.60 |
| Omecamtiv mecarbil | 2.19 | 34.01 |
CV—cardiovascular; HF—heart failure; Pbest—probability of each treatment being the best (%); SGLT2i—sodium-glucose cotransporter 2 inhibitors; SUCRA—surface under the cumulative ranking.